知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.02 秒)

    METHYLATION ALTERED DNA SEQUENCES AS MARKERS ASSOCIATED WITH HUMAN CANCER
    5.
    发明申请
    METHYLATION ALTERED DNA SEQUENCES AS MARKERS ASSOCIATED WITH HUMAN CANCER 审中-公开
    甲基化改变的DNA序列作为与人类癌症相关的标记

    公开(公告)号：US20100297641A1

    公开(公告)日：2010-11-25

    申请号：US12705485

    申请日：2010-02-12

    申请人： ISABEL D.C. MARKL ,  PETER A. JONES ,  YOSHITAKA TOMIGAHARA ,  GANGNING LIANG ,  HUALIN FU ,  JONATHAN CHENG

    发明人： ISABEL D.C. MARKL ,  PETER A. JONES ,  YOSHITAKA TOMIGAHARA ,  GANGNING LIANG ,  HUALIN FU ,  JONATHAN CHENG

    IPC分类号： C12Q1/68 ,  C07H21/04

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/154

    摘要： There is disclosed 103 novel methylation-altered DNA sequences (“marker sequences”) that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids.

    摘要翻译： 与正常组织相比，公开了103种与甲基化改变的DNA序列（“标记序列”）在癌症中具有不同的甲基化模式。 在许多情况下，这些标记序列代表在GenBank数据库中未发现的新的序列，并且这些标记序列之前没有关于人类癌症中甲基化模式的特征，包括但不限于膀胱和前列腺。 这103个序列具有治疗人类癌症的诊断，预后和治疗标记的效用，以及用于检测含甲基化CpG的核酸的试剂盒中的试剂。